Junctional adhesion molecule-A (JAM-A) is a transmembrane adhesive protein expressed at endothelial junctions and in leukocytes. In the present work, we found that DCs also express JAM-A. To evaluate the biological relevance of this observation, Jam-A -/-mice were generated and the functional behavior of DCs in vitro and in vivo was studied. In vitro, Jam-A -/-DCs showed a selective increase in random motility and in the capacity to transmigrate across lymphatic endothelial cells. In vivo, Jam-A -/-mice showed enhanced DC migration to lymph nodes, which was not observed in mice with endothelium-restricted deficiency of the protein. Furthermore, increased DC migration to lymph nodes was associated with enhanced contact hypersensitivity (CHS). Adoptive transfer experiments showed that JAM-A-deficient DCs elicited increased CHS in Jam-A +/+ mice, further supporting the concept of a DC-specific effect. Thus, we identified here a novel, non-redundant role of JAM-A in controlling DC motility, trafficking to lymph nodes, and activation of specific immunity.
Introduction
Junctional adhesion molecule-A (JAM-A) is a 32-kDa transmembrane glycoprotein present in endothelial cells, epithelial cells, platelets, and leukocytes. In the endothelium and several types of epithelia, JAM-A is located at intercellular junctions and codistributes with tight junction components (1) . Other members of the JAM family (JAM-B and JAM-C) have been recently identified (2, 3) . These molecules have a more restricted cell distribution but the same localization at tight junctions (4) (5) (6) .
The extracellular segment of JAM-A comprises two Ig-like domains, an amino terminal (VH type) and a carboxyl terminal (C2 type) fold, respectively. In solution, a recombinant soluble protein, which corresponds to the whole extracellular domain of JAM-A, binds in a homophilic manner, supporting the idea that JAM-A may mediate homotypic cell-to-cell adhesion (7) . X-ray structure analysis suggests that JAM-A forms parallel and noncovalent homodimers, which might expose at the cell surface an adhesive interface for homophilic interactions (8) .
Due to its junctional distribution, JAM-A may control transendothelial migration of leukocytes. We found that an anti-JAM-A mAb (BV11) was able to reduce infiltration of both monocytes and polymorphonuclear cells in in vivo models of inflammation in mice (1, 9) .
The mechanism of action of JAM-A in promoting cell transmigration remains undefined. It has been suggested that it may have a role in binding leukocytes and in directing their transmigration through endothelial junctions. JAM-A was found to link leukocyte integrin αL-β2 (10), but homophilic binding of endothelial and leukocytic JAM-A may also occur. More recent data (11) show that endothelial JAM-A can reorganize at junctions during leukocyte transmigration, creating a transient ring around transmigrating leukocytes. This suggests that JAM-A may actively promote the passage of the cells through the endothelial monolayer, possibly creating a tunnel-like structure at endothelial junctions.
DCs play a key role in the activation of specific immunity (12) , and trafficking to secondary lymphoid organs is crucial for their function. In the present paper we report that DCs express JAM-A. To assess the role of this protein in DC migration and in the activation of T cell responses, Jam-A -/-mice were generated. JAM-A-deficient mice showed increased in vitro and in vivo migration of DCs and increased contact hypersensitivity (CHS). Genetic analysis revealed that the role of JAM-A in DC trafficking is independent of its expression in the endothelium. Thus, JAM-A expression has a negative role in the regulation of DC migration to lymph nodes and activation of specific immunity.
Interbreeding of heterozygous mice for the Jam-A -allele generated heterozygous and homozygous offspring in the correct Mendelian ratios. DNA isolated from tail biopsies was used for genotyping the animals. Different combinations of flox JAM-A and/or Jam-A -alleles were identified by PCR using primers TS512 and TS379 and LoxP primers TS447 and TS444 as shown in Figure 1B. The absence of JAM-A was confirmed by FACS analysis of leukocytes ( Figure 1C ), Western blot, FACS analysis of endothelial cells ( Figure 1D ), and histological analysis of different organs (Figure 2) . At autopsy, mutant mice did not show significant alterations in organ development or morphology. The number of circulating platelets, lymphocytes, neutrophils, and monocytes was not significantly changed in Jam-A -/-animals compared with Jam-A +/+ animals (not shown). In addition, the pattern of the vasculature (mesenteric, ear skin) in the adult was not significantly different in Jam-A -/-mice compared with Jam-A +/+ mice as evaluated by the mean diameter of the vessels or number of branches per length unit (not shown) (14) . Basal and induced vascular permeability in the ear, measured as described (15) , was not significantly increased in Jam-A -/-mice compared with Jam-A +/+ mice.
To study the role of JAM-A specifically expressed on endothelial cells in regulating DC migration, a genetic approach was used. We crossed (see Methods) mice containing two floxed JAM-A alleles with heterozygous transgenic mice (Jam-A +/-) expressing Cre under the endothelium-specific promoter of Tie-2 (16) . By immunofluorescence staining (Figure 2 , A-C), JAM-A was undetectable in both vascular and lymphatic endothelial cells, but it retained its normal expression in epithelial cells. The identification of Tie-2 Cre-positive genotypes was done using Tie-2 Cre primers as shown in Figure 1B . To distinguish between the heterozygous Jam-A flox/-and Jam-A flox/+ mice, the primers TS379 and TS512 were used.
Increased migratory capacity of Jam-A -/-DCs. Previous studies have shown that JAM-A is expressed in myelomonocytic cells as well as in endothelial cells, where it was originally identified (1). These observations were extended to murine ( Figure 3A) and human (not shown) DCs. Murine bone marrow-derived DCs (BM-DCs) expressed JAM-A and its levels were not substantially affected by exposure to TNF-α, a classic maturation signal ( Figure 3A) . It was therefore important to investigate whether JAM-A deficiency affected DC function. Immature and mature Jam-A -/-DCs were similar to Jam-A +/+ DCs in terms of membrane phenotype ( Figure 3B ), mixed lymphocyte response ( Figure 3C ), and FITC-dextran uptake ( Figure 3D ).
To further investigate whether there were alterations of endogenous DCs in secondary lymphoid tissue, the phenotype of lymph node cells and DC subsets in lymph nodes were analyzed. As shown in Figure 4A , Jam-A +/+ and Jam-A -/-mice have a comparable pattern of lymphoid cell populations ( Figure 4A ) and subsets ( Figure 4B ) of myeloid, lymphoid, and plasmacytoid DCs.
The migratory properties of Jam-A -/-DCs were then investigated. As shown in Figure 5A , in a Transwell assay, Jam-A -/-DCs showed normal chemotactic responsiveness to chemokines that are preferentially active on immature (CCL3) and mature (CCL19) DCs.
Transendothelial migration was then investigated. As shown in Figure 5B , Jam-A -/-and Jam-A +/+ DC migration was equally low through blood microvascular endothelium (1G11 cells). In contrast, when mouse lymphatic endothelial cells (MELCs) were used, Jam-A -/-DCs showed a significant increase in transendothelial migration compared with Jam-A +/+ cells in both the apical-to-basal and the basal-to-apical directions.
When a more refined gold-track system was used to measure cell migration, Jam-A -/-DCs showed a marked increased in random motility compared with Jam-A +/+ cells ( Figure 5C ). When a JAM-A-blocking mAb was added to Jam-A +/+ mature DCs (mDCs) and immature DCs (iDCs), we observed a significant increase in random motility. The area covered by migrating cells in a typical experiment was 112.11 ± 16.56 μm 2 (mean ± SEM) for control iDCs and 337.31 ± 10.56 μm 2 for BV11-treated iDCs (20 μg/ml); 104.96 ± 13.96 μm 2 for control mDCs and 598.27 ± 17.36 μm 2 for BV11-treated mDCs. No significant effect was observed after adding an anti-PECAM/CD31 blocking mAb: 100.90 ± 10.01 μm 2 , mean ± SEM, for controls and 115.10 ± 21.05 μm 2 for Ab-treated (20 μg/ml) iDCs; 120.23 ± 18.01 μm 2 and 150.41 ± 15.33 μm 2 for control and Ab-treated mDCs, respectively.
We then investigated whether expression of membrane proteins relevant to DC trafficking (including the other two members of the JAM family, JAM-B and JAM-C) was altered in BM-DCs ( Figure  6A ) and lymphoid cells ( Figure 6B ). No significant difference was observed between Jam-A +/+ and Jam-A -/-cells.
These results show that Jam-A -/-DCs present increased migratory capacity, but only in selected in vitro systems (gold-track random migration and transmigration across lymphatic endothelium). It was therefore important to assess the actual in vivo relevance of the increased migratory ability of Jam-A -/-DCs. The FITC painting, contact sensitization assay was used to assess cutaneous DC migration in Jam-A -/-mice. FITC was applied to the skin of Jam-A +/+ and Jam-A -/-mice and the number of FITC/CD11c double-positive cells recovered from the draining lymph nodes was evaluated by FACS analysis. As shown in Figure 7A , the number of FITC + / CD11c + cells was significantly increased in Jam-A -/-mice compared with Jam-A +/+ mice.
To study the role of JAM-A specifically expressed on endothelial cells in regulating DC migration and trafficking to lymph nodes, the FITC painting assay was used with Tie-2 Cre Jam-A -/-mice. In these animals, in contrast to the CAG-Cre Jam-A -/-mice, there was no significant increase in DC migration to lymph nodes compared with Jam-A +/+ mice ( Figure 7B ); in fact there was a small but consistent decrease.
Defective CHS in Jam-A -/-mice. Previous work has shown that alterations in DC trafficking to lymph nodes are associated with defective activation of specific immunity (17, 18) . It was therefore of interest to assess the capacity of Jam-A -/-mice to mount specific immune responses. Jam-A -/-mice were studied in a CHS model with oxazolone (OXA) as sensitizing agent (see Methods). evaluated in normal skin sections. A weak and diffuse JAM-A positivity was observed in the epidermis as previously reported (1). Due to this pattern of reactivity, we were unable to correctly decipher JAM-A expression on epidermal LCs. In the dermis ( Figure  9D ), Jam-A +/+ cells were represented by keratinocytes of the pilar follicle, endothelium of dermal vessels, and scattered dermal cells with stellate/dendritic morphology ( Figure 9D , insert). JAM-A reactivity was absent in lymph nodes and cutaneous sections from Jam-A -/-mice (not shown).
Skin sections were immunostained for anti-MHC class II molecules to identify LCs in the epidermis. Similarly to Jam-A +/+ animals (not shown), MHC class II + LCs from Jam-A -/-mice were regularly distributed along the epidermis and exhibited normal morphology with fine and long dendrites ( Figure 9E ). In addition, LCs correctly expressed their specific marker Langerin ( Figure 9E, insert) . The density of LCs was evaluated in skin sections and the number of MHC-II + LCs was normalized to the number of DAPI + basal keratinocytes present in the same fields. No significant differences were observed in the number of LCs between Jam-A +/+ and Jam-A -/-mice: the mean number of LCs/100 basal keratinocytes was 9.9 ± 3.1 in Jam-A +/+ animals and 9.7 ± 2.2 in Jam-A -/-animals (mean ± SEM of 20 sections examined, P = 0.32 by Student's t test).
Twenty-four hours after FITC labeling of the skin, green fluorescent cells were evaluated in lymph node sections from Jam-A +/+ and Jam-A -/-mice by immunofluorescence microscopy. In Jam-A +/+ mice, green fluorescent cells were mainly located in the paracortical area and the majority of them expressed JAM-A ( Figure 9F ). In accordance with their LC origin, green fluorescent cells also expressed Langerin ( Figure 9G ) in both Jam-A +/+ and Jam-A -/-mice.
Discussion
This paper reports novel observations on the role of JAM-A in DC functional responses. We first found that DC cells express JAM-A on their surface. Jam-A -/-DCs showed an unexpected selective increase in random migration and transmigration across lymphatic endothelial cells. Moreover, Jam-A -/-mice showed increased localization to lymph nodes of skin DCs and enhanced CHS. Furthermore, in adoptive transfer experiments, Jam-A -/-DCs showed an increased capacity to activate a CHS reaction. Thus JAM-A plays a nonredundant role in tuning DC trafficking and subsequent activation of specific immunity.
The increased in vitro and in vivo migration of DCs in Jam-A -/-mice was unexpected. Previous in vitro and in vivo studies based on an anti-JAM-A mAb suggested that this molecule may facilitate monocyte and neutrophil transmigration and recruitment at sites of injury (9) . However, in in vitro experiments, the mAb was directed to endothelial cells and not to leukocytes. In this paper we report that increased migration to lymph nodes was not observed in mice with endothelium-restricted deficiency, which actually showed a small but consistent reduction in lymph node homing, supporting the idea of a positive role of endothelial JAM-A in promoting cell extravasation. In addition, we have unpublished data showing that neutrophil infiltration in a model of peritoneal inflammation is reduced in Jam-A -/-animals, consistent with the results obtained with the blocking mAb.
All together, these results suggest that JAM-A expressed in different cellular compartments may exert different and divergent influences and that the increased DC trafficking to lymph nodes observed in gene-targeted mice may be the net result of an alge- braic sum of negative and positive effects of JAM-A. The mechanism of endothelium-independent promotion of DC trafficking to lymph nodes in Jam-A -/-mice remains to be fully elucidated.
Results of our gold-track experiments support the idea that JAM-A may limit random DC motility, while this effect is overcome when cells are activated by strong chemotactic agents (see Figure 5A ). Transmigration through lymphatic but not blood endothelium is increased in Jam-A -/-DCs in vitro. Lymphatics allow dynamic interchanges of solutes and cells from lymph to tissues and vice versa. Consistent with this property, these cells present weak intercellular junctions with a specific molecular organization (19) (20) (21) . This may explain why DCs migrate more efficiently through lymphatic cells than blood endothelial cells and why the effect of JAM-A inactivation may be more evident in this system. Other possible explanations such as altered expression of chemokines seem unlikely, since the lymphatic endothelial cell line used in this work produces relatively low amounts of CCL21 and CCL19 by ELISA assay and Affymetrix gene chip array analysis (unpublished results). Moreover, JAM-A did not affect responsiveness to CCR7 ligands (see Figure 5A) .
At a molecular level, JAM-A can bind through its cytoplasmic tail different intracellular proteins containing PDZ domains. These include ZO-1, CASK, afadin/AF6, and the PAR3-PAR6-aPKC complex (22) (23) (24) (25) (26) . ZO-1, CASK, and afadin promote the anchorage of JAM-A to actin microfilaments (27) (28) (29) , and this effect may be important in the dynamic assembly and disassembly of the actin cytoskeleton during cell migration. In addition, the PAR3-PAR6-aPKC complex controls activation of glycogen synthase kinase-3β, which may regulate stability of microtubules and single cell motility (30) . It is possible that inactivation of the Jam-A gene causes uncontrolled activation/inhibition of these systems, leading to increased random cell migration.
In conclusion, in this paper we report for the first time a specific phenotype of Jam-A -/-animals. The data presented underline the complexity of the role of this molecule in regulating leukocyte traffic (31) . JAM-A may exert different, and in some cases contrasting, activities in different cell types. In DCs, JAM-A controls and limits cell motility while at endothelial cell junctions it may regulate and increase cell transmigration.
The proper localization of antigen-loaded DCs to secondary lymphoid organs is critical for an optimal activation of specific immunity (17, 18) . The increased migration of DCs to lymph nodes in Jam-A -/-mice was associated with increased CHS. Therefore, targeting JAM-A in an appropriate cellular context may represent a strategy to modulate activation of immune responses.
Methods

Construction of the Jam-A -/-transgene and production of Jam-A -/-mice.
To construct the targeting vector, three LoxP sites were inserted in the Jam-A gene: a LoxP site into the 5′ UTR region of exon 1 and a pGK-neo resistance cassette flanked by two other LoxP sites in opposite orientation into intron 1. Jam-A -/-mice were generated by crossing Jam-A flox/flox mice with CAG-Cre animals (13) . To identify the CAG-Cre alleles, the primers CAG-Cre-F (5′-CCAAAATTT-GCCTGCATTACCGGTCGATGC-3′) and CAG-Cre-R (5′-AGCGCCGTA-AATCAATCGATGAGTTGCTTC-3′) were used in PCR, generating an 800-bp product. Different combinations of WT, flox JAM-A, and Jam-A -alleles were identified by PCR using primer TS379 (5′-CCTCTCTTTTCACCAATCGGA-3′) and the antisense TS512 (5′-TCTTCTTCAGACGCCGAACCT-3′), which generate a 500-bp product for Jam-A -allele, an 800-bp product for WT allele, and a 3,000-bp product (showing no band) for flox allele. To distinguish between homozygous Jam-A -/-and and heterozygous flox JAM-A/Jam-Aalleles, the LoxP primers TS447 (5′-CGTATAATGTATGCTATACGAAG-3′) and the antisense TS444 (5′-GAGGTAGGGTCACAGATCACC-3′) were used (350-bp product in the presence of flox allele).
Endothelial Jam-A -/-mice were obtained as previously described (14) . For the identification of the Tie-2 Cre gene, the F-Tie-2 Cre primer (5′-CCCT-GTGCTCAGACAGAAATGAGA-3′) and the antisense primer Cre -(5′-CCAGCAGGCGCACCATTGCCCCTG-3′) were used in PCR, generating a 500-bp product. The Tie-2 Cre transgenic mice were a kind gift of Masashi Yanagisawa (University of Texas Medical Center) (16) .
Procedures involving animals and their care conformed to institutional guidelines in compliance with national (4D.L. N.116, G.U., suppl. 40, 18-2-1992) and international law and policies (EEC Council Directive 86/609, OJ L 358, 1, 12-12-1987 ; NIH Guide for the Care and Use of Laboratory Animals, US National Research Council 1996). All efforts were made to minimize the number of animals used and their suffering.
Cells and flow cytometry. Jam-A +/+ and Jam-A -/-endothelial cells were isolated from lungs and cultured as described in previous publications (32, 33) . The endothelial nature of the cells was confirmed by FACS analysis and immunofluorescence with S-Endo-1/MUC18 (34, 35), VE-cadherin (rat mAb BV13) (36), PECAM (rat mAb Mec 13.3) (37), and other endothelial markers (not shown). Fluorescence flow cytometric analysis was performed with a FACStar Plus apparatus (BD BiosciencesImmunocytometry Systems) as previously described (35), using an FITCconjugated donkey anti-rat Ab (Jackson ImmunoResearch Laboratories) as secondary Ab. JAM-A expression was analyzed using the anti-JAM-A mouse mAb BV12, as previously described (1).
MELCs were isolated from hyperplastic vessels (of liver and diaphragm) that were induced by intraperitoneal injection of incomplete Freund's adjuvant (38) . These cells are positive for lymphatic markers such as VEGFR-3 (Santa Cruz Biotechnology Inc.) and podoplanin (a kind gift of Dontscho Kerjaschki, University of Vienna, Vienna, Austria), and junction markers such as JAM-A and ZO-1 (Zymed Laboratories Inc.) (see Supplemental Figure 1 and Supplemental Table 1 ; supplemental material available at http://www.jci.org/cgi/content/full/114/5/729/ DC1). Other Ab's used to characterize the cells (see Supplemental Table  1) were LYVE (a kind gift of E. Ruoslahti, Cancer Research Center, The Burnham Institute, La Jolla, California, USA, and K. Alitalo, Biomedicum Helsinki, Helsinki University Central Hospital, Helsinki, Finland), JAM-C (a kind gift of B. Imhof, University of Geneva, Geneva, Switzerland), occludin (Zymed Laboratories Inc.), N-cadherin, and DSK (Ch1) (39) from BD Biosciences -Pharmingen.
For DC culture, 8-to 12-week-old Jam-A +/+ and Jam-A -/-male mice were used. Mouse DCs were generated from mouse CD34 + bone marrow cells as previously described (40) . Cells were characterized in terms of (a) membrane phenotype, (b) pinocytosis, and (c) mixed lymphocyte response on day 9 (40). Membrane phenotype was determined by expression of: DEC-205, identified by Ab HB-290 from the American Type Culture Collection (ATCC); CD86 (Ab HB-253, ATCC); I-A (anti-mouse MHC class II clone 2G9, BD Biosciences -Pharmingen); and CD80 (clone 1G10, BD Biosciences -Pharmingen). Where specified, DCs were cultured with TNF-α (20 ng/ml) for the last 24 hours of culture.
Other rat anti-mouse Ab's used to characterize DCs or secondary lymphoid tissues were: anti-CD18 (GAME-46, ATCC), anti-CD3 (145-2C11, ATCC), anti-CD19 (1D3, ATCC), allophycocyanin-conjugated (APC-conjugated) and FITC-conjugated anti-CD11b (M1/70, ATCC), PE-conjugated anti-CD11c (HL3, ATCC), PerCP-Cy5.5-conjugated anti-Gr-1 (RB6-8C5, ATCC), FITC-conjugated anti-CD45/B220 (RA3-6B2, ATCC), APC-conjugated anti-CD8α (clone 53-6.7, BD Biosciences -Pharmingen), antiCD11a (Tib-217, ATCC), anti-L-selectin (HB-132, ATCC), and anti-F4/80 (HB-198, ATCC). Rabbit anti-mouse JAM-B was a kind gift of Steve Rosen (University of California, San Francisco, California, USA).
Immunoprecipitation and Western blot on cell extracts were performed as previously described (22) . Immunostaining and DC counts. Mouse kidney, aorta, and lymph nodes were resected, embedded in Tissue-Tek OCT compound (Miles Inc.), snap frozen in liquid nitrogen, and stored at -80°C. Frozen tissues were then sectioned in 5-μm sections, fixed with methanol for 10 minutes at -20°C, and stained with anti-PECAM mAb Mec 13.3 (37) and anti-JAM-A mAb BV12 (1), followed by FITC-or Cy3-conjugated donkey anti-rat Ab's (Jackson ImmunoResearch Laboratories). Frozen lymph nodes were fixed in acetone for 10 minutes at -20°C and double stained with rat anti-mouse JAM-A (BV12) and rabbit anti-mouse LYVE overnight at 4°C, followed by Cy3 donkey anti-rat and FITC goat anti-rabbit Ab's (Jackson ImmunoResearch Laboratories). Fluorescence images of immunostained tissues were analyzed with a Leica DMR fluorescence microscope, and images were recorded with a Hamamatsu 3CCD camera before processing with Adobe Photoshop for Macintosh.
Thin tissue sections from lymph nodes were obtained and stained with H&E for morphological evaluation. For immunofluorescence and immunohistochemistry using an indirect immunoperoxidase technique, lymph nodes and small fragments of mouse ears were embedded and frozen in Tissue-Tek OCT compound. Three-micron sections were air-dried overnight, fixed in acetone for 10 minutes, and incubated with 10% normal rabbit serum. Sections were then incubated with different primary Ab's including rat anti-mouse JAM-A (BV12), anti-MHC class II (clone 2G9, BD Biosciences -Pharmingen), and anti-Langerin (a kind gift of G. Trinchieri, Schering-Plough Corp., Dardilly, France). Primary Ab's were revealed with anti-rat biotinylated secondary Ab's (Vector Laboratories Inc.) followed by Texas red-or FITC-conjugated streptavidin. Slides were mounted in 90% glycerol and analyzed with an Olympus BX60 fluorescence microscope.
Quantitative analysis of epidermal LCs expressing MHC class II was performed by evaluating 30 high-power fields (magnification ×400) obtained from nonconsecutive ear sections. LC numbers were determined by counting MHC class II-positive cells with recognizable stellate morphology and normalizing for the number of basal keratinocytes; data are expressed as mean number of LCs/100 keratinocytes (41) .
Cytokines. Human CCL3 and CCL19 were from PeproTech Inc. Mouse GM-CSF was from Sandoz Inc. Murine TNF-α was a kind gift from P. Vandenabeele (Gent University, Belgium). Human Flt3 ligand was a generous gift from Immunex Corp. Cytokines were endotoxin free as assessed by Limulus amebocyte assay (BioWhittaker Inc.).
Chemotaxis and transmigration assays. Chemotaxis and transendothelial migration experiments were performed in polycarbonate Transwell inserts (5-μm pore, Corning Costar Corp.) as previously described (40) , with minor modifications. 51 Cr-labeled DCs (15 × 10 4 /well in 0.1 ml for chemotaxis and 5 × 10 4 / well in 0.1 ml for transmigration) were seeded in the upper compartment and chemoattractants were placed in the lower compartment. After 90 minutes of incubation at 37°C, the radioactivity present in the lower compartment was evaluated. Chemokines were used at the optimal concentration of 100 ng/ ml. Results are reported as percentage of input, as in the following formula: (cpm in the lower compartment/cpm of the input) × 100. In transmigration experiments, MELCs (38) or the microvascular mouse endothelial cell line 1G11 (40) were grown as monolayers on gelatin-or fibronectin-coated inserts; labeled DCs were applied to the monolayers. In some experiments the MELCs were grown on the upper or lower side of the filter.
Phagokinetic track assay. The assay was performed as described (42) . Briefly, cells were plated onto glass coverslips previously coated with colloidal gold and incubated for 24 hours at 37°C. Then cells were fixed with 3% paraformaldehyde and observed by light microscopy. Pictures of individual cells were analyzed with NIH Image software for measuring the particlefree area and counting the number of tracks produced by each cell.
In some experiments, BM-DCs from Jam-A +/+ mice were incubated during the track assay with anti-JAM-A mAb BV11 (1, 9) and anti-PECAM mAb Mec 13.3 (37) as negative control (20 μg/ml).
FITC skin painting. The number of lymph node DCs after FITC skin painting was analyzed as described previously (43) . In brief, FITC (Sigma-Aldrich) was dissolved (5 mg/ml) in a 50:50 (vol/vol) acetone-dibutylphthalate mixture just before application. Mice were painted on the shaved abdomen with 0.2 ml of this FITC solution. Inguinal lymph nodes were obtained after 6 hours and 24 hours, mechanically disaggregated, and treated with a mixture of collagenase A (1 mg/ml, Roche Molecular Biochemicals) and DNase (0.4 mg/ml, Roche Molecular Biochemicals) for 30 minutes at 37°C, followed by DNase alone at room temperature for 15 minutes. Cell suspensions were then stained with a PE-labeled hamster anti-mouse CD11c mAb (clone HL3, BD BiosciencesPharmingen) and PE/FITC double-positive cells were analyzed by FACScan. E) , and Langerin + LCs (red cells, inset in E; G). Magnification: ×40 in A, ×200 in F and G, ×400 in B, D, and E, and ×600 in insert in A, C, insert in D, and insert in E. Scale bars: 500 μm in A, 50 μm in B, 20 μm in C, and 100 μm in F.
CHS. CHS was induced and determined as previously described (44) . Briefly, the hapten 4-ethoxymethylene-2-phenyl-2-oxazoline-5-one (oxazolone; OXA) (Sigma-Aldrich) was freshly prepared before CHS assays. For sensitization, mice were painted once (day 0) on the shaved abdominal skin with 100 μl of 3% OXA in 4:1 acetone/olive oil (vol/vol) solution. Five days later (day +5) mice were challenged by the application of 10 μl of OXA (1%) on each side of the right ear, while the left ear received the vehicle alone. CHS response was determined by measuring the degree of ear swelling of the antigen-painted ear compared with that of the vehicle-treated contralateral ear at different times after challenge (from 24 to 96 hours) using a dial thickness gauge (Mitutoyo America Corp.). The results were expressed as mean percent of increased swelling calculated over vehicle-treated contralateral ear.
In some experiments CHS was induced by in vivo inoculation of antigenloaded DCs (45) . Cultured BM-DCs were resuspended in HBSS containing 100 μg/ml DNBS (ICN Biomedicals Inc.) and incubated at 37°C for 30 minutes. For sensitization (day 0), 4 × 10 5 DNBS-treated DCs (in 200 μl of saline) from Jam-A +/+ or Jam-A -/-mice were injected subcutaneously into the flank of Jam-A +/+ recipient mice. Five days later, mice were challenged by the application of 10 μl 0.2% 2,4-dinitrofluorobenzene (Sigma-Aldrich) in 4:1 acetone/olive oil solution on each side of the right ear. Some animals were challenged by the application of 10 μl 1% OXA on each side of the right ear, as negative controls. The left ear received vehicle alone. Groups of mice injected with the same number of unmodified DCs, or not injected and challenged with vehicle alone, served as negative controls. CHS response was determined by measuring ear swelling as reported above for OXA.
Statistical analysis. Experimental groups included at least five mice. All experiments were performed at least three times. Statistical significance was evaluated using the two-tailed or the paired Student's t test, as indicated.
